A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U Meeting Abstract
| Authors: | Jackman, D. M.; Jegede, O.; Zauderer, M. G.; Mitchell, E. P.; Zwiebel, J.; Gray, R. J.; Li, S.; McShane, L.; Rubinstein, L.; Patton, D. R.; Williams, P. M.; Hamilton, S. R.; Conley, B. A.; Arteaga, C. L.; Harris, L.; O'Dwyer, P. J.; Chen, A. P.; Flaherty, K. |
| Abstract Title: | A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120601261 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.3087 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3087 -- Source: Wos |
